Long-term follow-up of photodynamic therapy of cervical intraepithelial neoplasia grade 2 (CIN2).
Photodiagnosis Photodyn Ther
; 47: 104219, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38768844
ABSTRACT
BACKGROUND:
To determine the long-term efficacy and safety of 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) for treating cervical intraepithelial neoplasia grade 2 (CIN2) as well as the suitability of ALA-PDT in treating of cervical lesions divided into cervical transformation zone type 3.METHODS:
We included 81 patients diagnosed with CIN2 at the Department of Gynecology of the Affiliated Hospital of Qingdao University with data collected between January 2019 and January 2021 following ALA-PDT. Furthermore, we analyzed the superiority of ALA-PDT in fertility preservation among women of childbearing age based on follow-up data from 11 patients with fertility requirements.RESULTS:
Our findings confirmed the long-term efficacy of ALA-PDT for CIN2 treatment, with an overall efficacy of 95.83 % (23/24) at follow-up of 25-36 months. Moreover, the cervical transformation zone type 3 improvement and human papillomavirus (HPV)-negative efficacy were 69.2 % (18/26) and 82.4 % (14/17), respectively. ALA-PDT is recommended for consenting patients with cervical transformation zone type 3. Additionally, women without primary infertility could experience natural pregnancy and full-term birth of more than one baby following ALA-PDT for CIN2 treatment, with a satisfaction rate of ≈100 %.CONCLUSIONS:
ALA-PDT is recommendable for treating high-grade squamous intraepithelial lesions, especially in patients with fertility requirements.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fotoquimioterapia
/
Displasia do Colo do Útero
/
Neoplasias do Colo do Útero
/
Fármacos Fotossensibilizantes
/
Ácido Aminolevulínico
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Photodiagnosis Photodyn Ther
Assunto da revista:
DIAGNOSTICO POR IMAGEM
/
TERAPEUTICA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China